Cara Therapeutics (CARA)
$0.68
0.02 (2.24%)
CARA Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
37.40M
PE Ratio
-0.31
EPS
-2.19
Volume (Avg. Vol.)
169,234
Day's Range
$0.68 - $0.73
52-Week Range
$0.50 - $4.67
Dividend & Yield
N/A (N/A)
CARA Stock Predictions, Articles, and Cara Therapeutics News
CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today
Shares of CARA stock are ticking higher on Tuesday after the Cara Therapeutics' injection treatment was approved by the FDA.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! We're getting ready for another busy day of trading with a dive into the biggest pre-market stock movers for Tuesday.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning
Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open.
Why This Just Might Be the Biggest Week for CARA Stock
Cara stock is up ahead of its presentations at Kidney Week 2019. Unless it reports bad news, Cara Therapeutics looks ready to run.
Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use
It's not a great reason in and of itself to buy CGC stock , but Canopy Growth does have an overlooked presence in the medical cannabis arena.
With Trial Results Due, This Could Be a Breakout Year for Cara Stock
Putting in the work may pay off big for In 2018, setting up the clinical studies dominated Cara Therapeutics' activities. For 2019, the study results may drive Cara stock higher. stock
Cara Therapeutics Stock Could Outperform in 2019
CARA stock could be meaningfully boosted by drug development updates in 2019
The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock
Growing pressure to take action against China's illicit drug production could make investors more interested in CARA stock, potentially causing Cara Therapeutics stock to rally.
Why Cara Therapeutics Stock Is Soaring Today
Cara Therapeutics (CARA) shares were up more than 11% on Wednesday as the company received good news regarding its latest clinical trial.
3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc. (HCSG)
Square (SQ) continues its breathtaking 2017 rally Wednesday, Cara Therapeutics (CARA) jumps on trial results and Healthcare Services Group (HCSG) scores a post-earnings bump.
